cite
articl
davi
jl
schirmer
j
medlin
e
pharmacokinet
pharmacodynam
clinic
use
trazodon
activ
metabolit
mchlorophenylpiperazin
hors
j
vet
pharmacol
therap
trazodon
serotonin
receptor
antagonist
reuptak
inhibitor
use
extens
anxiolyt
human
small
anim
veterinari
medicin
aim
studi
determin
pharmacokinet
oral
trazodon
experiment
hors
evalu
effect
oral
trazodon
clinic
hors
six
experiment
hors
administ
trazodon
mgkg
plasma
concentr
trazodon
metabolit
mcpp
determin
via
uplcmsm
noncompartment
pharmacokinet
analysi
sedat
ataxia
score
determin
trazodon
rapidli
absorb
oral
administr
maximum
concentr
halflif
termin
phase
approxim
hr
metabolit
present
low
level
hors
repres
total
area
curv
experiment
hors
concentrationdepend
sedat
ataxia
note
last
hr
clinic
case
medic
record
hors
treat
trazodon
variou
abnorm
behaviour
review
data
summar
trazodon
success
modifi
behaviour
problem
degre
clinic
case
toler
subsequ
lack
drug
effect
occur
two
clinic
case
follow
day
use
popul
hors
advers
effect
attribut
trazodon
includ
oversed
muscl
fascicul
transient
arrhythmia
stall
rest
prescrib
mani
hors
follow
orthopaed
injuri
surgeri
sever
ill
hors
toler
confin
well
due
tempera
issu
separ
situat
anxieti
lack
acclim
hors
may
walk
incessantli
weav
crib
rear
buck
kick
stall
wall
behaviour
problem
may
contribut
delay
wound
heal
new
injuri
recrudesc
ill
well
damag
stall
distress
owner
manag
techniqu
environment
social
enrich
free
choic
access
feed
often
attempt
may
success
appropri
case
herbal
supplement
calm
product
avail
use
variou
amino
acid
well
magnesium
effect
howev
littl
scientif
data
avail
judg
product
alway
effect
environment
enrich
supplement
calm
agent
work
medic
often
tri
commonli
use
agent
acepromazin
fluphenazin
reserpin
carri
unaccept
risk
advers
event
advers
effect
ascrib
drug
make
necessari
find
safer
altern
manag
stall
rest
trazodon
hydrochlorid
triazolopyridin
deriv
member
phenylpiperazin
class
drug
classifi
serotonin
antagonist
reuptak
inhibitor
base
primari
pharmacolog
mechan
action
antagon
serotonin
receptor
secondari
mechan
inhibit
serotonin
reuptak
stahl
trazodon
activ
metabolit
mchlorophenylpiperazin
mcpp
also
agonist
effect
serotonin
receptor
odagaki
toyoshima
yamauchi
trazodon
use
extens
small
anim
medicin
anxiolyt
without
behaviour
modifi
drug
gruen
sherman
orlando
case
thomson
griffith
sherman
steven
et
al
success
use
drug
veterinari
speci
make
attract
altern
use
hors
worthi
studi
speci
reduct
anxieti
stallrest
hors
improv
anim
welfar
current
one
publish
report
trazodon
adult
hors
knych
mama
steffey
stanley
kass
howev
publish
report
use
drug
clinic
case
therefor
object
studi
determin
pharmacokinet
trazodon
activ
metabolit
speci
follow
singl
oral
dose
mgkg
well
determin
whether
administr
result
sedat
ataxia
advers
effect
final
use
daili
trazodon
clinic
patient
present
veterinari
teach
hospit
report
six
healthi
adult
geld
age
year
weigh
kg
use
studi
breed
includ
four
quarter
hors
two
appendix
quarter
hors
hors
hous
stabl
begin
day
prior
drug
administr
durat
studi
water
grass
hay
avail
ad
libitum
throughout
studi
except
hay
withheld
hr
hr
drug
administr
studi
approv
north
carolina
state
univers
institut
anim
care
use
committe
protocol
ethic
legal
requir
follow
physiolog
data
heart
rate
respiratori
rate
bodi
temperatur
mucou
membran
colour
capillari
refil
time
record
prior
drug
administr
min
hr
postadministr
gastrointestin
sound
evalu
auscult
dorsal
ventral
quadrant
side
score
present
absent
quadrant
assign
gi
motil
score
rang
time
point
auscult
perform
period
per
quadrant
faecal
output
time
first
faecal
product
record
hors
also
monitor
advers
effect
includ
sign
colic
roll
flank
watch
excess
paw
stretch
abnorm
behaviour
sedat
ataxia
score
determin
use
score
system
adapt
literatur
solano
valverd
desroch
nykamp
bour
wojtasiakwypart
et
al
wong
et
al
score
perform
time
point
correspond
physic
examin
gener
physic
examin
perform
prior
blood
collect
sedat
ataxia
score
perform
blood
collect
time
point
coincid
sedat
score
assign
describ
tabl
ataxia
score
grade
follow
none
stabl
sway
slightli
sway
lean
sway
lean
cross
limb
buckl
hors
baselin
score
determin
zero
score
system
use
random
twoway
crossov
design
trazodon
hydrochlorid
form
commerci
avail
mg
tablet
teva
pharmaceut
sellersvil
pa
usa
administ
oral
three
hors
hors
ac
randomli
assign
receiv
mgkg
dose
first
follow
mgkg
dose
three
hors
hors
df
receiv
mgkg
first
follow
mgkg
dose
round
nearest
complet
tablet
actual
dose
rang
mgkg
high
low
dose
respect
minimum
washout
period
allow
administr
administ
drug
dose
divid
two
cathet
tip
syring
tablet
dissolv
cc
warm
water
min
light
corn
syrup
ml
ad
increas
viscos
palat
result
suspens
administ
oral
interdent
space
hors
head
elev
min
ensur
administr
entir
dose
oral
administr
achiev
within
min
tablet
content
mix
corn
syrup
determin
effect
sampl
site
plasma
concentr
wast
blood
ml
aspir
intraven
jugular
cathet
syring
discard
blood
sampl
ml
collect
immedi
place
lithium
heparincontain
plastic
blood
tube
sampl
collect
cathet
flush
ml
heparin
salin
plasma
sampl
centrifug
rpm
g
min
plasma
separ
ml
cryogen
storag
tube
sampl
store
analysi
plasma
sampl
store
month
prior
analysi
longterm
stabil
trazodon
mcpp
describ
prior
public
kale
agraw
gupta
patel
patel
libo
et
al
concentr
trazodon
metabolit
mcpp
determin
ultrahigh
pressur
liquid
chromatographi
tandem
mass
spectrometri
use
method
valid
laboratori
equin
plasma
calibr
curv
prepar
daili
fortifi
volum
sampl
standard
inject
class
acquiti
uplc
xevotqd
mass
spectromet
water
corpor
milford
usa
initi
mobil
phase
consist
formic
acid
water
solut
formic
acid
acetonitril
solut
b
initi
condit
set
solut
solut
b
min
follow
solut
solut
b
min
return
initi
condit
min
mobil
phase
run
rate
mlmin
separ
achiev
use
acquiti
uplc
beh
phenyl
column
assay
valid
qualiti
assur
perform
accord
publish
guidelin
shah
midha
digh
calibr
curv
prepar
analys
daili
use
six
calibr
sampl
blank
unfortifi
sampl
calibr
curv
deem
accept
coeffici
determin
r
valu
calibr
standard
backcalcul
within
true
valu
blank
sampl
anim
analys
ensur
select
assay
accuraci
report
deviat
true
valu
precis
measur
deviat
mean
accuraci
precis
deem
accept
valu
less
concentr
use
lower
limit
detect
llod
lower
limit
quantit
lloq
report
lowest
concentr
detect
quantifi
calibr
curv
respect
overal
lloq
trazodon
llod
intraday
accuraci
precis
assay
determin
qualiti
control
qc
sampl
use
spike
equin
plasma
concentr
repres
high
medium
low
concentr
rang
high
low
calibr
curv
trazodon
accuraci
within
true
valu
precis
within
mean
concentr
metabolit
mcpp
lloq
llod
intraday
accuraci
precis
assay
determin
three
concentr
rang
low
standard
curv
mcpp
accuraci
within
true
valu
precis
within
mean
concentr
drug
concentr
analys
use
commerci
avail
softwar
phoenix
winnonlin
version
certara
usa
inc
princeton
nj
usa
determin
pharmacokinet
paramet
hors
noncompartment
analysi
use
determin
maximum
plasma
concentr
c
max
time
c
max
max
termin
rate
constant
z
halflif
termin
phase
total
area
curv
auc
trazodon
mcpp
follow
oral
administr
statist
analysi
perform
use
commerci
avail
softwar
sigmaplot
systat
softwar
inc
san
jose
ca
usa
data
normal
assess
use
shapirowilk
equal
varianc
test
chang
normal
distribut
data
includ
heart
rate
respiratori
rate
temperatur
mgkg
dose
well
differ
sedat
ataxia
score
dose
level
analys
use
oneway
repeat
measur
analysi
varianc
rmanova
chang
nonnorm
distribut
data
includ
gastrointestin
sound
temperatur
mgkg
dose
well
differ
sedat
ataxia
score
compar
baselin
analys
use
friedman
rmanova
rank
linear
regress
analysi
use
determin
relat
combin
trazodon
mcpp
plasma
concentr
effect
base
sedat
ataxia
score
pair
test
use
determin
differ
normal
distribut
data
includ
pharmacokinet
paramet
c
max
auc
trazodon
metabolit
mgkg
dose
group
well
differ
jugular
cephal
drug
concentr
time
first
defec
total
number
faecal
pile
first
hr
nonnorm
distribut
data
max
mannwhitney
rank
sum
test
use
analys
differ
dose
group
statist
signific
set
p
valu
medic
record
hors
present
veterinari
teach
hospit
prescrib
trazodon
search
determin
clinic
safeti
efficaci
data
collect
includ
signal
present
complaint
number
day
trazodon
dose
use
usag
concurr
reserpin
advers
effect
attribut
trazodon
administr
respons
trazodon
classifi
satisfactori
unsatisfactori
base
assess
treat
clinician
plasma
concentr
time
trazodon
mcpp
depict
figur
b
trazodon
detect
plasma
hors
min
oral
administr
either
mgkg
reach
maximum
concentr
min
metabolit
mcpp
detect
hors
min
hors
min
follow
administr
either
mg
kg
reach
maximum
concentr
min
metabolit
prepar
hors
although
present
low
amount
repres
total
auc
trazodon
plu
metabolit
signific
differ
plasma
concentr
note
blood
collect
site
p
halflif
termin
phase
trazodon
moder
approxim
hr
affect
dose
mcpp
variabl
averag
approxim
hr
mgkg
hr
mgkg
relev
pharmacokinet
paramet
summar
tabl
trazodon
signific
differ
max
detect
dose
group
trend
toward
higher
c
max
note
mgkg
dose
group
compar
mgkg
group
p
signific
differ
detect
auc
mgkg
dose
group
mgkg
dose
group
p
signific
differ
detect
pharmacokinet
paramet
mcpp
hors
receiv
either
dose
display
degre
sedat
ataxia
begin
earli
min
administr
signific
differ
detect
sedat
score
ataxia
score
differ
dose
despit
lack
statist
signific
onset
sedat
ataxia
mgkg
dose
group
delay
compar
mgkg
group
mgkg
dose
sedat
score
significantli
increas
min
compar
overal
drug
well
toler
experiment
hors
oversed
defin
either
sedat
ataxia
score
accompani
refus
eat
common
advers
effect
note
seen
three
hors
hors
b
mg
kg
dose
none
mgkg
dose
transient
arrhythmia
detect
two
hors
hors
e
f
mgkg
dose
one
postdos
one
postdos
electrocardiogram
b
l
e
noncompartment
pharmacokinet
paramet
trazodon
follow
administr
mgkg
oral
six
hors
f
g
u
r
e
sedat
ataxia
b
score
time
hors
n
administ
singl
oral
dose
trazodon
hydrochlorid
mgkg
baselin
score
time
zero
hors
score
system
denot
statist
differ
baselin
read
perform
howev
base
auscult
sinu
arrhythmia
ventricular
prematur
contract
consid
abnorm
rhythm
detect
resolv
within
min
initi
diagnosi
one
hors
also
show
muscl
fascicul
biopsi
affect
skin
reveal
eosinophil
perivascular
dermat
oedema
epiderm
spongiosi
consist
acut
allerg
reaction
treatment
dexamethason
mg
intramuscularli
semimembranosu
muscl
medic
bath
initi
hors
respond
favour
within
hr
taper
dose
dexamethason
administ
day
complet
resolut
sign
achiev
sign
recur
reintroduct
drug
second
phase
crossov
experi
medic
record
hors
receiv
trazodon
sed
identifi
includ
geld
six
mare
one
stal
result
studi
indic
trazodon
effect
oral
drug
use
hors
facilit
stall
rest
recoveri
trazodon
rapidli
absorb
hors
studi
actual
extent
absorpt
could
determin
due
lack
intraven
dose
intraven
dose
perform
due
unaccept
level
advers
effect
note
dog
hors
includ
tachycardia
aggressionexcit
whole
bodi
tremor
jay
et
al
knych
et
al
addit
lack
commerci
avail
inject
formul
make
intraven
dose
unlik
clinic
relev
pharmacokinet
oral
formul
demonstr
moder
approxim
hr
follow
administr
either
mgkg
dose
mgkg
knych
et
al
report
hr
lack
signific
differ
dose
like
indic
linear
pharmacokinet
within
small
dose
rang
significantli
increas
auc
note
mgkg
dose
compar
mgkg
demonstr
increas
drug
exposur
higher
dose
also
support
linear
kinet
previou
studi
report
auc
hrml
mgkg
oral
knych
et
al
f
g
u
r
e
effect
trazodon
hydrochlorid
bodi
temperatur
hors
n
administ
singl
oral
dose
trazodon
hydrochlorid
mgkg
valu
differ
superscript
letter
differ
significantli
time
point
p
auc
auc
report
mgkg
mean
hrml
respect
discrep
may
repres
differ
absorpt
drug
base
formul
method
administr
present
studi
use
commerci
avail
trazodon
tablet
administ
via
syring
wherea
previou
studi
use
trazodon
powder
administ
feed
differ
absorpt
profil
formul
support
differ
note
max
report
use
tablet
result
mean
max
hr
wherea
administr
powder
form
feed
result
max
approxim
hr
bioavail
report
knych
et
al
caution
use
extrapol
data
commerci
avail
tablet
form
although
trend
toward
higher
c
max
differ
signific
lack
signific
c
max
like
due
small
number
anim
use
well
method
administr
use
studi
oral
administr
instead
intragastr
administr
use
close
mimic
treatment
clinic
patient
despit
best
practic
use
deliv
oral
medic
small
amount
drug
lost
deliveri
may
contribut
variabl
note
c
max
addit
factor
may
contribut
variabl
lack
fast
prior
drug
administr
done
close
mimic
treatment
clinic
patient
hors
stall
rest
frequent
fed
free
choic
hay
order
keep
occupi
throughout
day
studi
hors
fed
two
flake
hay
pm
night
prior
dose
allow
eat
hr
prior
dose
hors
finish
feed
other
still
hay
left
time
feed
pull
therefor
amount
feed
stomach
may
affect
rate
extent
drug
reach
small
intestin
avail
absorpt
baggot
human
absorpt
trazodon
irregular
fast
subject
improv
food
intak
c
max
concentr
lower
max
increas
feed
nilsen
dale
howev
due
differ
diet
human
hors
actual
effect
feed
may
differ
effect
feed
drug
absorpt
remain
investig
drug
oral
administr
subsequ
collect
blood
sampl
jugular
vein
may
lead
fals
elev
plasma
concentr
due
direct
absorpt
sublingu
vessel
drain
jugular
vein
oral
administr
trazodon
produc
degre
sedat
ataxia
experiment
hors
durat
sedat
rang
hr
mgkg
dose
respect
durat
ataxia
rang
hr
mgkg
dose
respect
longer
durat
ataxia
report
compar
sedat
mgkg
dose
due
one
hors
ataxia
score
time
point
hors
return
ataxia
score
hr
administr
degre
sedat
ataxia
produc
highli
variabl
among
hors
may
due
factor
affect
absorpt
previous
discuss
includ
method
administr
effect
feed
administr
mgkg
sedat
without
signific
ataxia
document
five
six
hors
suggest
dosedepend
respons
knych
et
al
inform
highlight
need
dose
tailor
base
individu
anim
respons
linear
relationship
exist
plasma
concentr
sedat
ataxia
score
mgkg
dose
oversed
note
three
six
hors
behaviour
calm
effect
dog
seen
concentr
jay
et
al
threshold
concentr
describ
human
treat
major
depress
order
mihara
et
al
studi
hors
within
expect
therapeut
rang
dog
least
hr
follow
administr
either
dose
hors
also
reach
threshold
concentr
human
follow
administr
either
dose
sedat
score
return
baselin
concentr
ataxia
score
return
normal
concentr
hors
studi
lower
concentr
note
ataxia
score
relat
one
outlier
hors
grade
ataxia
score
hr
longer
hors
exclus
hors
data
analysi
result
concentr
result
ataxia
overal
result
studi
suggest
behaviour
calm
concentr
trazodon
mcpp
approxim
normal
anim
behaviour
calm
concentr
clinic
hors
trazodon
prescrib
would
expect
variabl
depend
individu
anim
tempera
degre
anxieti
minim
physiolog
effect
associ
trazodon
administr
experiment
hors
clinic
signific
chang
note
relat
heart
rate
respiratori
rate
gut
sound
signific
chang
note
relat
bodi
temperatur
particularli
mgkg
dose
group
bodi
temperatur
significantli
decreas
multipl
time
point
follow
administr
trazodon
phenomenon
previous
report
hors
knych
et
al
knych
et
al
howev
evid
hors
current
studi
advers
drug
event
ade
note
trial
oversed
frequent
ade
previous
discuss
two
hors
also
develop
arrhythmia
muscl
fascicul
transient
short
durat
lower
dose
trazodon
mgkg
po
note
caus
arrhythmia
chang
percentag
atrioventricular
block
note
administ
healthi
hors
undergo
fit
train
knych
et
al
trazodon
associ
arrhythmia
human
includ
prolong
qt
interv
ventricular
prematur
contract
torsad
de
point
tarantino
appleton
lansdel
effect
commonli
note
peopl
preexist
caus
ventricular
irrit
therefor
use
drug
hors
preexist
cardiac
diseas
drug
may
prolong
qt
interv
perform
caution
caus
muscl
fascicul
note
hors
arrhythmia
unknown
may
relat
gener
sedat
ataxia
arrhythmia
auscult
short
durat
deem
unlik
associ
hypoxiarel
muscl
weak
effect
trazodon
skelet
muscl
ion
channel
report
use
trazodon
clinic
patient
deem
success
subject
caus
degre
sedat
modifi
advers
behaviour
associ
stall
rest
case
hors
still
requir
addit
sedat
prolong
pain
procedur
due
retrospect
natur
aspect
studi
durat
action
specif
avail
one
hors
stallion
respond
dose
hors
difficult
due
extrem
agit
estim
dose
success
deliv
oral
repeat
higher
dose
attempt
due
report
associ
trazodon
administr
priapism
human
warner
peabodi
whiteford
hollist
although
patient
show
sign
priapism
given
fact
stallion
use
breed
risk
treatment
base
potenti
effect
consid
high
attend
clinician
owner
four
hors
determin
oversed
initi
dose
trazodon
administ
common
reason
clinician
determin
decreas
dose
necessari
eat
hr
drug
administr
three
hors
receiv
decreas
dose
one
hors
maintain
initi
dose
two
hors
develop
appar
toler
drug
one
hors
initi
administ
trazodon
mgkg
po
daili
drug
lost
effect
day
hors
switch
alphacasozepin
good
effect
anoth
hors
receiv
initi
dose
mgkg
po
daili
produc
oversed
dose
decreas
mgkg
effect
period
approxim
week
time
dose
increas
approxim
mgkg
effect
short
durat
approxim
hr
develop
toler
trazodon
report
speci
notabl
dog
clinic
trial
trazodon
postsurg
confin
dog
owner
request
increas
dosag
treatment
start
week
follow
surgeri
gruen
roe
griffith
hamilton
sherman
two
hors
demonstr
sever
muscl
fascicul
follow
singl
dose
drug
discontinu
hors
receiv
drug
within
hr
follow
gener
anaesthet
event
potenti
indic
pharmacodynam
interact
trazodon
anaesthet
drug
use
trazodon
use
success
postsurg
canin
patient
advers
effect
worthi
drug
discontinu
note
howev
dose
begin
day
surgeri
initi
low
dose
gruen
et
al
ade
note
experiment
hors
colic
dermat
arrhythmia
note
clinic
case
six
clinic
hors
origin
treat
reserpin
either
prior
time
admiss
facilit
stall
rest
littl
clinic
effect
use
trazodon
alon
combin
reserpin
consid
superior
reserpin
treatment
alon
case
advers
effect
note
alreadi
describ
reserpin
dowl
trazodon
stahl
may
caus
hypotens
effect
coadministr
two
drug
may
addit
therefor
caution
use
concurr
consecut
administr
trazodon
reserpin
two
four
clinic
case
deem
oversed
studi
treat
concurr
reserpin
conclus
trazodon
use
altern
oral
sed
hors
demonstr
behaviour
issu
rest
variou
medic
condit
dosag
regimen
like
need
tailor
base
individu
hors
respons
although
ade
note
hors
describ
report
short
durat
necessarili
requir
discontinu
drug
studi
investig
pharmacokinet
trazodon
follow
multipl
dose
concurr
administr
sed
anaesthet
medic
warrant
well
safeti
use
drug
hors
may
ridden
administr
sampl
collect
process
perform
north
carolina
state
univers
colleg
veterinari
medicin
larg
anim
analysi
laboratori
author
conflict
interest
report
jld
involv
studi
design
execut
sampl
collect
analysi
manuscript
prepar
submiss
js
em
